Amgen Inc (AMGN) 148.05 $AMGN
Express Scripts Includes Praluent and Repatha in Formulary
Zacks Equity Research - Zacks Investment Research - 1 hr 59 mins ago
Pharmacy benefit manager Express Scripts (ESRX) announced that it will include two new cholesterol-lowering drugs -- Regeneron/Sanofi's (REGN/SNY) Praluent and Amgen's (AMGN) Repatha -- on its National Preferred Formulary.
ABT: 40.63 (+0.74), ESRX: 82.57 (+1.27), AMGN: 148.05 (+6.83), SNY: 48.33 (-0.61), REGN: 485.76 (+25.94)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 4.96% Rise
Comtex SmarTrend(R) - 2 hrs ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.24 to a high of $148.31. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $144.90 on volume of 7.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 148.05 (+6.83)
Amgen Rises 4.96% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - 2 hrs 1 min ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.24 to a high of $148.31. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $144.90 on volume of 7.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 148.05 (+6.83)
The Medicines Co. Ties Up with SymBio for Ionsys in Japan
Zacks Equity Research - Zacks Investment Research - 2 hrs 7 mins ago
The Medicines Company (MDCO) signs up with Tokyo-based SymBio Pharmaceuticals for Ionsys in Japan.
ENDP: 63.14 (-0.96), MDCO: 36.00 (+0.67), APRI: 1.65 (+0.02), AMGN: 148.05 (+6.83)
Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay
Arpita Dutt - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Amgen (AMGN) and Regeneron (REGN) should benefit from Express Scripts' decision to place both their PCSK9 inhibitors on its National Preferred Formulary.
BIIB: 279.24 (+3.25), ONCE: 44.81 (-5.59), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55), ACOR: 29.94 (+0.23), FOLD: 7.01 (+0.71), REGN: 485.76 (+25.94)
Infinity (INFI) Updates on Duvelisib and IPI-549 on R&D Day
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:45PM CDT
Infinity (INFI) provided an update on the clinical development program and commercial overview on duvelisib and IPI-549 on its R&D Day.
AMGN: 148.05 (+6.83), INFI: 7.79 (-0.24), ABBV: 55.63 (+0.55), ANIK: 32.27 (+0.60)
Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 94.30 (-0.50), BIIB: 279.24 (+3.25), FB: 92.40 (-0.40), XOM: 79.20 (+1.31), AMGN: 148.05 (+6.83), LLY: 83.99 (-0.18), BMY: 60.55 (+0.67), INTC: 32.31 (+0.57), CELG: 116.98 (+4.79), WWAV: 41.76 (-0.20), MSFT: 46.80 (+0.05), TWTR: 29.83 (+2.21), CVX: 88.12 (+1.13), GIS: 55.72 (+0.02)
Cholesterol Busters Will Be Cheaper but Remain Top Sellers
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 07, 11:02AM CDT
Image source: Flickr user stockmonkeys.com. Pharmacy benefit manager Express Scripts runs drug programs for major health insurers and self-insured employers and that means that it's faced with the tough task of negotiating prices for new drugs,...
ESRX: 82.57 (+1.27), AMGN: 148.05 (+6.83), SNY: 48.33 (-0.61), REGN: 485.76 (+25.94)
Amgen (AMGN) Crosses Pivot Point Resistance at $143.71
Comtex SmarTrend(R) - Wed Oct 07, 10:26AM CDT
Shares of Amgen (NASDAQ:AMGN) opened today above their pivot of $140.88 and have already reached the first level of resistance at $143.71. Investors may be interested in a cross of the next upside pivot targets of $146.19 and $151.50.
AMGN: 148.05 (+6.83)
Stock Market News for October 07, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 9:10AM CDT
Benchmarks finished mixed on Tuesday after a selloff in healthcare stocks offset gains in energy and materials shares
KMI: 32.14 (+0.36), BIIB: 279.24 (+3.25), MON: 88.06 (-0.02), AMGN: 148.05 (+6.83), XOM: 79.20 (+1.31), COP: 55.27 (+0.13), SLB: 75.35 (+1.41), CELG: 116.98 (+4.79), LYB: 95.59 (+1.96), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), CVX: 88.12 (+1.13), DOW: 47.49 (+0.41), REGN: 485.76 (+25.94), ECL: 118.27 (+1.08)
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
AMGN: 148.05 (+6.83), CVS: 101.01 (+1.19), TEVA: 58.55 (+0.58), ABBV: 55.63 (+0.55), LLY: 83.99 (-0.18)
Amgen Turning the Tables on 'Generic' Competition
Cory Renauer, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Wikimedia Commons If you're one of the world's largest biotechnology companies, what do you do when others try eating your lunch? Amgen (NASDAQ: AMGN) isn't about to take it lying down. In the face of competition for its blockbuster...
AMGN: 148.05 (+6.83)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Global B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2015 - 21 Companies & 31 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtsp4f/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Advancell - Amgen Inc. - BioNovion B.V. - Celgene Corporation - Dynavax Technologies Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - iDD biotech SAS - Immunomedics, Inc. - Johnson & Johnson - Juno Therapeutics Inc. - Nippon Shinyaku Co., Ltd. - Noxxon Pharma AG - Ono Pharmaceutical Co., Ltd. - Regeneron Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - TheraMAB LLC - Vivia Biotech, S.L. Drug Profiles - 202-b - AB-8779 - acadesine - alemtuzumab biosimilar - AMG-319 - bafetinib - BION-1301 - Cell Therapy for Hematological Malignancies - Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Cell Therapy to Target CD16 for CLL and NHL - Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Cell Therapy to Target CD19 for Cancer - Cell Therapy to Target CD19 for Oncology - Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - E-7449 - GNKS-356 - IDD-001 - IDD-002 - ilorasertib - JNJ-64052781 - lenalidomide - MAT-303 - olaptesed pegol - ONO-4059 - REGN-1979 - SD-101 - TAB-08 - tocilizumab - Vivia-009 For more information visit http://www.researchandmarkets.com/research/jt...ll_chronic
DVAX: 24.29 (-0.24), JNJ: 94.98 (+1.56), IMMU: 2.07 (-0.01), AMGN: 148.05 (+6.83), JUNO: 48.74 (+1.42), ABBV: 55.63 (+0.55), REGN: 485.76 (+25.94), CELGZ: 1.75 (+0.08)
Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 23.11 (+1.56), IMMU: 2.07 (-0.01), AMGN: 148.05 (+6.83), GSK: 39.72 (-0.05), BMY: 60.55 (+0.67), JNJ: 94.98 (+1.56), ARGS: 5.73 (+0.33), ANTH: 6.24 (+0.46), ABBV: 55.63 (+0.55), CBMG: 18.15 (+1.19), KPTI: 12.30 (+0.86), CELGZ: 1.75 (+0.08)
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
PR Newswire - Wed Oct 07, 12:46AM CDT
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages. The personalized medicine (global) market is presented as follows:
AMGN: 148.05 (+6.83)
Express Scripts to cover pricey new cholesterol treatments
By TOM MURPHY - AP - Tue Oct 06, 7:32PM CDT
The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol but raise concern over prices that can top $14,000 a year.
ESRX: 82.57 (+1.27), UNH: 116.43 (+0.38), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94)
Business Highlights
By The Associated Press - AP - Tue Oct 06, 5:14PM CDT
___
AMGN: 148.05 (+6.83), MSFT: 46.80 (+0.05), AAPL: 110.78 (-0.53), REGN: 485.76 (+25.94), PEP: 98.52 (+1.45)
Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:40PM CDT
Merck (MRK) announced that results from a phase III study on a chronic hepatitis C virus combination regimen of elbasvir and grazoprevir were published in The Lancet.
GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55)
Amgen Announces Repatha(TM) Co-Preferred Position on Express Scripts National Formulary
PR Newswire - Tue Oct 06, 4:06PM CDT
Amgen (NASDAQ: AMGN) today announced that Express Scripts will provide access to Repatha(TM) (evolocumab) through its national formulary.
AMGN: 148.05 (+6.83)
Express Scripts Includes Praluent and Repatha in Formulary
Zacks Equity Research - Zacks Investment Research - 1 hr 59 mins ago
Pharmacy benefit manager Express Scripts (ESRX) announced that it will include two new cholesterol-lowering drugs -- Regeneron/Sanofi's (REGN/SNY) Praluent and Amgen's (AMGN) Repatha -- on its National Preferred Formulary.
ABT: 40.63 (+0.74), ESRX: 82.57 (+1.27), AMGN: 148.05 (+6.83), SNY: 48.33 (-0.61), REGN: 485.76 (+25.94)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 4.96% Rise
Comtex SmarTrend(R) - 2 hrs ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.24 to a high of $148.31. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $144.90 on volume of 7.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 148.05 (+6.83)
Amgen Rises 4.96% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - 2 hrs 1 min ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.24 to a high of $148.31. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $144.90 on volume of 7.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 148.05 (+6.83)
The Medicines Co. Ties Up with SymBio for Ionsys in Japan
Zacks Equity Research - Zacks Investment Research - 2 hrs 7 mins ago
The Medicines Company (MDCO) signs up with Tokyo-based SymBio Pharmaceuticals for Ionsys in Japan.
ENDP: 63.14 (-0.96), MDCO: 36.00 (+0.67), APRI: 1.65 (+0.02), AMGN: 148.05 (+6.83)
Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay
Arpita Dutt - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Amgen (AMGN) and Regeneron (REGN) should benefit from Express Scripts' decision to place both their PCSK9 inhibitors on its National Preferred Formulary.
BIIB: 279.24 (+3.25), ONCE: 44.81 (-5.59), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55), ACOR: 29.94 (+0.23), FOLD: 7.01 (+0.71), REGN: 485.76 (+25.94)
Infinity (INFI) Updates on Duvelisib and IPI-549 on R&D Day
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:45PM CDT
Infinity (INFI) provided an update on the clinical development program and commercial overview on duvelisib and IPI-549 on its R&D Day.
AMGN: 148.05 (+6.83), INFI: 7.79 (-0.24), ABBV: 55.63 (+0.55), ANIK: 32.27 (+0.60)
Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 94.30 (-0.50), BIIB: 279.24 (+3.25), FB: 92.40 (-0.40), XOM: 79.20 (+1.31), AMGN: 148.05 (+6.83), LLY: 83.99 (-0.18), BMY: 60.55 (+0.67), INTC: 32.31 (+0.57), CELG: 116.98 (+4.79), WWAV: 41.76 (-0.20), MSFT: 46.80 (+0.05), TWTR: 29.83 (+2.21), CVX: 88.12 (+1.13), GIS: 55.72 (+0.02)
Cholesterol Busters Will Be Cheaper but Remain Top Sellers
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 07, 11:02AM CDT
Image source: Flickr user stockmonkeys.com. Pharmacy benefit manager Express Scripts runs drug programs for major health insurers and self-insured employers and that means that it's faced with the tough task of negotiating prices for new drugs,...
ESRX: 82.57 (+1.27), AMGN: 148.05 (+6.83), SNY: 48.33 (-0.61), REGN: 485.76 (+25.94)
Amgen (AMGN) Crosses Pivot Point Resistance at $143.71
Comtex SmarTrend(R) - Wed Oct 07, 10:26AM CDT
Shares of Amgen (NASDAQ:AMGN) opened today above their pivot of $140.88 and have already reached the first level of resistance at $143.71. Investors may be interested in a cross of the next upside pivot targets of $146.19 and $151.50.
AMGN: 148.05 (+6.83)
Stock Market News for October 07, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 9:10AM CDT
Benchmarks finished mixed on Tuesday after a selloff in healthcare stocks offset gains in energy and materials shares
KMI: 32.14 (+0.36), BIIB: 279.24 (+3.25), MON: 88.06 (-0.02), AMGN: 148.05 (+6.83), XOM: 79.20 (+1.31), COP: 55.27 (+0.13), SLB: 75.35 (+1.41), CELG: 116.98 (+4.79), LYB: 95.59 (+1.96), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), CVX: 88.12 (+1.13), DOW: 47.49 (+0.41), REGN: 485.76 (+25.94), ECL: 118.27 (+1.08)
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
AMGN: 148.05 (+6.83), CVS: 101.01 (+1.19), TEVA: 58.55 (+0.58), ABBV: 55.63 (+0.55), LLY: 83.99 (-0.18)
Amgen Turning the Tables on 'Generic' Competition
Cory Renauer, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Wikimedia Commons If you're one of the world's largest biotechnology companies, what do you do when others try eating your lunch? Amgen (NASDAQ: AMGN) isn't about to take it lying down. In the face of competition for its blockbuster...
AMGN: 148.05 (+6.83)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Global B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2015 - 21 Companies & 31 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtsp4f/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Advancell - Amgen Inc. - BioNovion B.V. - Celgene Corporation - Dynavax Technologies Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - iDD biotech SAS - Immunomedics, Inc. - Johnson & Johnson - Juno Therapeutics Inc. - Nippon Shinyaku Co., Ltd. - Noxxon Pharma AG - Ono Pharmaceutical Co., Ltd. - Regeneron Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - TheraMAB LLC - Vivia Biotech, S.L. Drug Profiles - 202-b - AB-8779 - acadesine - alemtuzumab biosimilar - AMG-319 - bafetinib - BION-1301 - Cell Therapy for Hematological Malignancies - Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Cell Therapy to Target CD16 for CLL and NHL - Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Cell Therapy to Target CD19 for Cancer - Cell Therapy to Target CD19 for Oncology - Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - E-7449 - GNKS-356 - IDD-001 - IDD-002 - ilorasertib - JNJ-64052781 - lenalidomide - MAT-303 - olaptesed pegol - ONO-4059 - REGN-1979 - SD-101 - TAB-08 - tocilizumab - Vivia-009 For more information visit http://www.researchandmarkets.com/research/jt...ll_chronic
DVAX: 24.29 (-0.24), JNJ: 94.98 (+1.56), IMMU: 2.07 (-0.01), AMGN: 148.05 (+6.83), JUNO: 48.74 (+1.42), ABBV: 55.63 (+0.55), REGN: 485.76 (+25.94), CELGZ: 1.75 (+0.08)
Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 23.11 (+1.56), IMMU: 2.07 (-0.01), AMGN: 148.05 (+6.83), GSK: 39.72 (-0.05), BMY: 60.55 (+0.67), JNJ: 94.98 (+1.56), ARGS: 5.73 (+0.33), ANTH: 6.24 (+0.46), ABBV: 55.63 (+0.55), CBMG: 18.15 (+1.19), KPTI: 12.30 (+0.86), CELGZ: 1.75 (+0.08)
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
PR Newswire - Wed Oct 07, 12:46AM CDT
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages. The personalized medicine (global) market is presented as follows:
AMGN: 148.05 (+6.83)
Express Scripts to cover pricey new cholesterol treatments
By TOM MURPHY - AP - Tue Oct 06, 7:32PM CDT
The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol but raise concern over prices that can top $14,000 a year.
ESRX: 82.57 (+1.27), UNH: 116.43 (+0.38), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94)
Business Highlights
By The Associated Press - AP - Tue Oct 06, 5:14PM CDT
___
AMGN: 148.05 (+6.83), MSFT: 46.80 (+0.05), AAPL: 110.78 (-0.53), REGN: 485.76 (+25.94), PEP: 98.52 (+1.45)
Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:40PM CDT
Merck (MRK) announced that results from a phase III study on a chronic hepatitis C virus combination regimen of elbasvir and grazoprevir were published in The Lancet.
GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55)
Amgen Announces Repatha(TM) Co-Preferred Position on Express Scripts National Formulary
PR Newswire - Tue Oct 06, 4:06PM CDT
Amgen (NASDAQ: AMGN) today announced that Express Scripts will provide access to Repatha(TM) (evolocumab) through its national formulary.
AMGN: 148.05 (+6.83)
